Healthcare
Immunome, Inc.(IMNM)
Live Price
Offline$18.53
+3.46% today
1Y Change
+113.48%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $2.02B
- Revenue Growth
- -23.2%
- EPS Growth
- +51.4%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immunome, Inc. (IMNM) is a Healthcare stock with a market cap of $2.02B and listed on NASDAQ. The stock last traded around $18.53 and up 113.5% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -23.2%, EPS growth of +51.4%, a dividend yield of 0.0%. What stands out right now is revenue -23.2%, EPS +51.4%, free cash flow -22.1% with operating margin -3084.8% and ROIC -33.5%. Valuation already assumes a fairly strong business story at price/sales 290.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IMNM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-23.2% vs +7.6% peer median
Operating Margin
Below sector median
-3084.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -23.2% and EPS is at +51.4%, with operating margin around -3084.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -1.3% | -13.5% | -20.0% |
2026 Mar 3, 2026 | -27.1% | +4.5% | +1.5% | +1.5% |
2025 Nov 6, 2025 | -14.0% | -1.7% | +6.5% | +27.5% |
Benchmark Edge
IMNM vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMNM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMNM Max Drawdown
-33.59%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMNM and SPY.
Company Overview
Immunome, Inc.
NASDAQ Capital Market
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
- Leadership
- Clay Siegall
- IPO Date
- Oct 2, 2020
- Employees
- 131
- Street Address
- 665 Stockton Drive
- Mailing
- Bothell, PA, 19341
- Region
- Bothell, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 321 3700
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 290.4
- Price/Book
- 3.2
Growth
- Revenue
- -23.2%
- EPS
- +51.4%
- Free Cash Flow
- -22.1%
Profitability
- Gross Margin
- -630.3%
- Operating Margin
- -3084.8%
- Net Margin
- -3060.0%
- ROE
- -57.6%
- ROIC
- -33.5%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 14.69
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.